tirzepatide removed from fda shortage list to reconsider removal of Eli Lilly weight loss drug Out of Shortage, Into Controversy:

Sermorelin Sermorelin is proven to increase metabolic rate, enhance weight loss, improve insulin sensitivity and increase lean muscle mass

Eli Lillys orforglipron Phase III trial (ATTAIN-MAINTAIN) enabled injectable-to-oral transitions, preserving most weight loss over 52 weeks

Such research endeavors may reveal novel pathways and strategies for the treatment of gout

J Biol Chem 289:63326340

Pharmacy benefit managers: The powerful middlemen inflating drug costs and squeezing main street pharmacies [Interim Staff Report]

PEVs loaded with MCC950 (an NLRP3 inflammasome inhibitor) reduced atherosclerotic plaque formation and localized vascular inflammation [89,90,91,92], highlighting PEVs as biocompatible, autologous drug carriers [93]